Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 3/20 | 0.50 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | BRD1 | O95696 | 1/20 | 0.40 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7491601 | 0.87 | CYP11B2 (0.46) | BRPF1SMARCA2CYP11B2CYP11B1KDM4E | |
| SCHEMBL8029433 | 0.80 | NTRK1 (0.46) | BRPF1SMARCA2KDM4ELMNAALDH1A1 | |
| SCHEMBL7491020 | 0.80 | BRPF1 (0.42) | BRPF1SMARCA2CYP11B2CYP11B1KMT2A | |
| SCHEMBL10022436 | 0.80 | BRPF1 (0.44) | BRPF1SMARCA2CYP11B2CYP11B1ACSS2 | |
| SCHEMBL9959510 | 0.79 | CCR2 (0.49) | CYP11B2CYP11B1KDM4EALDH1A1S1PR1 | |
| SCHEMBL21335575 | 0.78 | BRPF1 (0.44) | BRPF1SMARCA2CYP11B2CYP11B1ACSS2 | |
| SCHEMBL10053515 | 0.77 | BRPF1 (0.45) | BRPF1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL7958147 | 0.77 | NTRK1 (0.57) | BRPF1SMARCA2ACSS2BRD1BRPF3 | |
| SCHEMBL9581147 | 0.77 | KMT2A (0.47) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL7488753 | 0.76 | MAPT (0.56) | BRPF1KDM4ELMNAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590950-B1 | N-CYCLYL-3-(CYCLYLCARBONYLAMINOMETHYL)BENZAMIDE DERIVATIVES AS RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-15 | — | — | EP | disclosed |
| US-20120165322-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165322-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOA | BRPF1 3073/4885SMARCA2 1271/4885CYP11B2 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.